JPMorgan Chase & Co’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-171
| Closed | -$215 | – | 6175 |
|
|
2025
Q1 | $215 | Buy |
171
+166
| +3,320% | +$209 | ﹤0.01% | 5914 |
|
|
2024
Q4 | $11 | Sell |
5
-7
| -58% | -$15 | ﹤0.01% | 6254 |
|
|
2024
Q3 | $40 | Sell |
12
-5
| -29% | -$17 | ﹤0.01% | 6083 |
|
|
2024
Q2 | $86 | Buy |
17
+10
| +143% | +$51 | ﹤0.01% | 5891 |
|
|
2024
Q1 | $60 | Buy |
7
+2
| +40% | +$17 | ﹤0.01% | 5981 |
|
|
2023
Q4 | $19 | Buy |
5
+2
| +67% | +$8 | ﹤0.01% | 6314 |
|
|
2023
Q3 | $8 | Buy |
3
+2
| +200% | +$5 | ﹤0.01% | 6352 |
|
|
2023
Q2 | $21 | Sell |
1
-198
| -99% | -$4.16K | ﹤0.01% | 5880 |
|
|
2023
Q1 | $10K | Buy |
+199
| New | +$10K | ﹤0.01% | 5265 |
|
|
2022
Q3 | – | Sell |
-12,471
| Closed | -$516K | – | 5520 |
|
|
2022
Q2 | $516K | Sell |
12,471
-3,942
| -24% | -$163K | ﹤0.01% | 3845 |
|
|
2022
Q1 | $827K | Buy |
16,413
+3,535
| +27% | +$178K | ﹤0.01% | 3733 |
|
|
2021
Q4 | $773K | Sell |
12,878
-16,835
| -57% | -$1.01M | ﹤0.01% | 3830 |
|
|
2021
Q3 | $1.47M | Sell |
29,713
-16,840
| -36% | -$834K | ﹤0.01% | 3366 |
|
|
2021
Q2 | $2.65M | Sell |
46,553
-7,143
| -13% | -$407K | ﹤0.01% | 3054 |
|
|
2021
Q1 | $3.09M | Buy |
53,696
+27,535
| +105% | +$1.58M | ﹤0.01% | 2968 |
|
|
2020
Q4 | $1.78M | Buy |
26,161
+25,451
| +3,585% | +$1.73M | ﹤0.01% | 3038 |
|
|
2020
Q3 | $172K | Buy |
710
+112
| +19% | +$27.1K | ﹤0.01% | 3797 |
|
|
2020
Q2 | $101K | Sell |
598
-4,267
| -88% | -$721K | ﹤0.01% | 3957 |
|
|
2020
Q1 | $339K | Buy |
4,865
+4,731
| +3,531% | +$330K | ﹤0.01% | 3483 |
|
|
2019
Q4 | $9K | Buy |
+134
| New | +$9K | ﹤0.01% | 4506 |
|
|
2018
Q4 | – | Sell |
-6,900
| Closed | -$395K | – | 4845 |
|
|
2018
Q3 | $395K | Sell |
6,900
-1,772
| -20% | -$101K | ﹤0.01% | 3587 |
|
|
2018
Q2 | $507K | Buy |
+8,672
| New | +$507K | ﹤0.01% | 3444 |
|
|
2017
Q4 | – | Sell |
-1,106
| Closed | -$68K | – | 4650 |
|
|
2017
Q3 | $68K | Buy |
+1,106
| New | +$68K | ﹤0.01% | 3742 |
|